ASMB Common Stock · Transaction Jan 4, 2021 · Filed Feb 17, 2021 · Amount pending receipt enrichment
Assembly Biosciences Inc
Veridion Score
BETAHIGH CONF · 6/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is ASMB moving today?
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
ASMB overview
Related filings and maps
Congress activity in ASMB
ASMB Common Stock · Transaction Dec 28, 2020 · Filed Feb 10, 2021 · Amount pending receipt enrichment
ASMB contract awards, year to date.
Public federal awards linked to this ticker.
ASMB lobbying filings, year to date.
Registered lobbying filings matched to Assembly Biosciences Inc.